Last reviewed · How we verify
sirolimus and oseltamivir
This combination uses sirolimus (an mTOR inhibitor) to suppress immune responses and promote autophagy, while oseltamivir (a neuraminidase inhibitor) blocks viral replication of influenza.
This combination uses sirolimus (an mTOR inhibitor) to suppress immune responses and promote autophagy, while oseltamivir (a neuraminidase inhibitor) blocks viral replication of influenza. Used for Severe influenza or COVID-19 (investigational combination therapy).
At a glance
| Generic name | sirolimus and oseltamivir |
|---|---|
| Sponsor | Chinese University of Hong Kong |
| Drug class | mTOR inhibitor + neuraminidase inhibitor combination |
| Target | mTOR (sirolimus); influenza neuraminidase (oseltamivir) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Sirolimus inhibits the mTOR pathway, reducing T-cell proliferation and promoting autophagy, which may enhance antiviral immunity and reduce excessive inflammatory responses. Oseltamivir inhibits influenza neuraminidase, preventing viral release from infected cells. The combination is hypothesized to provide both direct antiviral activity and immunomodulation to improve outcomes in severe viral infections.
Approved indications
- Severe influenza or COVID-19 (investigational combination therapy)
Common side effects
- Immunosuppression / increased infection risk
- Gastrointestinal disturbance (nausea, diarrhea)
- Hyperglycemia
- Hyperlipidemia
- Thrombocytopenia
Key clinical trials
- Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza (PHASE3)
- Rapamune Improves Outcomes of Severe H1N1 Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sirolimus and oseltamivir CI brief — competitive landscape report
- sirolimus and oseltamivir updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI